Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato) titanium(IV) compounds against Walker 256 carcinosarcoma. A new class of antineoplastic agents.
The antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compounds against Walker 256 carcinosarcoma in comparison to cis-dichlorodiammineplatinum(II) (cisplatin, cis-DDP, NSC 119875) was investigated. The tested compounds showed in this experimental model an enhanced median survival time and a lower toxicity compared to cisplatin.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002279:Carcinoma 256, Walker / Q000188:drug therapy*; D005260:Female; D009942:Organometallic Compounds / Q000627:therapeutic use*; D051381:Rats; D013997:Time Factors; D014025:Titanium / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; C036107:dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV); D014025:Titanium